CysLTR1 inhibition by ZK or Montelukast has been used to treat asthma since the nineties3, but the potential of CysLTR1 as a pharmacological target for the treatment of neurodegenerative disorders, such as Alzheimer’s disease (AD), has become a topic of interest because the leukotriene system targets AD pathologies on multiple levels56. This evidence concerns the gene CYSLTR1 and early-onset autosomal dominant Alzheimer disease.